mp4co
Sickle Cell-Hemoglobin C Disease Syndrome
Floatz Rating
B59/100
Confidence
Indicative
Sponsor
Sangart
Modality
UNKNOWN
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
44Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01925001CT.gov Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis | — | Withdrawn | — | — | — |
NCT01356485CT.gov Safety Study of MP4CO in Adult Sickle Cell Patients | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Sickle Cell-Hemoglobin C Disease Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| mp4co (this asset) | Sangart | P2 | B · 59 |
| Hydroxyurea | Nova Laboratories Limited | P2 | BB |
| Busulfanum | Tami D. John | P2 | CCC |
| Prednisone | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | P2 | CCC |
| Fludarabine | National Institute of Allergy and Infectious Diseases (NIAID) | P2 | CCC |
| Tacrolimus | National Institute of Allergy and Infectious Diseases (NIAID) | P2 | CCC |
| Magnesium Pidolate | St. Jude Children's Research Hospital | P2 | CCC |
| Recombinant-Methionyl Human Stem Cell Factor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | P1 | CC |
| Tovinontrine | Cardurion Pharmaceuticals, Inc. | P1 | CC |
+6 more in the Sickle Cell-Hemoglobin C Disease Syndrome cohort
Other indications for mp4co
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Sickle Cell Disease | — | P2 | B · 59 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. mp4co in Sickle Cell-Hemoglobin C Disease Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/mp4co-sickle-cell-hemoglobin-c-disease-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →